Skip to content

Your cart

(0 Items)

You don't have any items in your cart just yet. Curious? Explore our sachet below.

Gutcultured 30 days on a white background

Gutcultured

Ready to invest in your future?

Good for your gut, microbiota, Immune system, Gut-Brain Axis and long lasting health effects for life.

€0,00

Add €70,00 for free shipping. Nearly there!

€70,00

You might want to add an extra month:

Gutcultured 30 days on a white background

Gutcultured

One-month, one-time purchase

Regular price €59,50

Unit price €59,50 / per item

Add VAT number

VAT Number

Your VAT number is valid

Enter a valid VAT number

Subtotal

€0,00

Tax included. Shipping calculated at checkout.

🍂 Back to your Routine — Lifestyle Subscription — 50% off your first month 🍂

Free EU Shipping from €70

Product
Science
About

Product
Science
About

Landing Page - 2025 - Educational - Ari-1

Clinically Proven. Lifestyle-ready.

Product

Gutcultured Rebalance
Science

Help

My Account
Contact

Follow us

Instagram
Twitter
LinkedIn

Legal

Privacy Policy
Terms & Conditions
Shipping Policy
Return Policy

© Gutcultured - 2026

Disclaimer

Food supplements cannot replace a varied, balanced diet and a healthy lifestyle.
Do not exceed the recommended daily dose.
Excessive consumption may produce laxative effects.
Please inform and consult your doctor before consuming this product.
Safe for children from 3 years, pregnant and breastfeeding women.

References

Gut Health - BB-12 gut health (regularity / comfort)

1 Eskesen D, Jespersen L, Michelsen B, et al. Br J Nutr. 2015;114(10):1638–1646. PMID: 26382580. - Adults with low defecation frequency; BB-12 increased defecation frequency vs placebo and supported more regular bowel movements.

2 Pitkälä KH, Strandberg TE, Finne-Soveri H, et al. J Nutr Health Aging. 2007;11(4):305–311. PMID: 17653486. - Elderly nursing home residents; BB-12 increased the proportion of days with normal bowel function compared with control.

Gut Health - LGG / LGG+BB-12 gut health

3 Armuzzi A, Cremonini F, Bartolozzi F, et al. Aliment Pharmacol Ther. 2001;15(2):163–169. PMID: 11148433. DOI: 10.1046/j.1365-2036.2001.00923.x - Adults on H. pylori triple therapy; LGG reduced antibiotic-associated GI side effects such as diarrhea, nausea and taste disturbance vs placebo.

4 Hauser G, Salkic N, Vukelić K, Jajac-Knez A, Stimac D. Medicine (Baltimore). 2015;94(17):e685. PMID: 25929897. DOI: 10.1097/MD.0000000000000685 - Adults undergoing H. pylori eradication; LGG + BB-12 improved eradication rates and reduced multiple GI side effects compared with antibiotics alone.

Immune Support - BB-12 immune support (vaccine response, adults)

5 Rizzardini G, Eskesen D, Calder PC, et al. Br J Nutr. 2012;107(6):876–884. PMID: 21899798. DOI: 10.1017/S0007114511004407 - Healthy adults; BB-12 enhanced systemic and mucosal antibody responses to influenza vaccination, supporting immune function.

Immune Support - LGG immune support (URTIs, day-care children)

6 Hojsak I, Snovak N, Abdović S, et al. Clin Nutr. 2010;29(3):312–316. PMID: 19896252. DOI: 10.1016/j.clnu.2009.08.002 - Day-care children; LGG reduced the incidence and duration of upper respiratory tract infections and days with symptoms vs placebo.

Resilience: evidenced in adult trials where LGG and BB-12 helped maintain gut comfort and treatment success during intensive antibiotic regimens.

7 Armuzzi A, Cremonini F, Ojetti V, et al. Digestion. 2001;63(1):1–7. PMID: 11244256. DOI: 10.1159/000051869 - Adults on H. pylori triple therapy; LGG improved overall tolerability of treatment by lowering the frequency and severity of GI side effects.

8 Cremonini F, Di Caro S, Covino M, et al. Am J Gastroenterol. 2002;97(11):2744–2749. PMID: 12425545. DOI: 10.1111/j.1572-0241.2002.07063.x - Adults receiving H. pylori eradication therapy; regimens including LGG reduced GI side effects such as diarrhea and taste disturbance without compromising eradication.

9 Tuomola EM, Salminen SJ. J Dairy Sci. 1998;81(1):49–55. PMID: 9493080. DOI: 10.3168/jds.S0022-0302(98)75550-2 - In vitro study; LGG showed good survival in simulated gastric juice and bile, supporting high acid and bile tolerance.

Potency - LGG – survivability, acid/bile tolerance, long-term stability

10 Kankainen M, Paulin L, Tynkkynen S, et al. Proc Natl Acad Sci U S A. 2009;106(40):17193–17198. PMID: 19805152. DOI: 10.1073/pnas.0908876106 - Genomic and functional work; identified SpaCBA pili in LGG that mediate strong mucus adhesion and prolonged persistence in the human gut.

11 Novonesis (Chr. Hansen) – LGG® technical / stability data and sales presentation. Internal dossier, 2024. - Internal technical documentation; reports long-term genomic stability, high survivability through manufacturing and transport, and robust shelf-life performance for LGG.

12 Fredua-Agyeman M, Gaisford S. Int J Pharm. 2017;517(1–2):96–103. PMID: 28254415. DOI: 10.1016/j.ijpharm.2016.12.044 - Formulation and in vitro GI model; BB-12 retained viability in optimized formulations and survived simulated gastrointestinal conditions, indicating delivery of live cells to the gut.

Potency - BB-12 – survival, microbiota modulation, shelf-life

13 Volokh O, Klimenko N, Berezhnaya Y, et al. Nutrients. 2019;11(3):547. PMID: 30836671. DOI: 10.3390/nu11030547 - Healthy adults; 30 days of BB-12–fortified yoghurt increased fecal B. animalis abundance and modulated microbiota function with a stable overall community.

14 Chr. Hansen / Novonesis – BB-12® application and stability data (capsules and fermented products). Technical dossier, various years. - Internal application data; demonstrate that BB-12 maintains label-claimed potency through production and shelf life in multiple delivery formats.

Other Studies:

15 Arvola T, Laiho K, Torkkeli S, et al. Pediatrics. 1999;104(5):e64. PMID: 10545590. DOI: 10.1542/peds.104.5.e64 - Children on antibiotics for respiratory infections; LGG reduced antibiotic-associated diarrhea from 16% to 5% and improved markers linked to mucosal barrier protection.

16 Vanderhoof JA, Whitney DB, Antonson DL, et al. J Pediatr. 1999;135(5):564–568. PMID: 10547243. DOI: 10.1016/S0022-3476(99)70053-3 - Children receiving oral antibiotics; LGG reduced the incidence of antibiotic-associated diarrhea and improved stool consistency during treatment.

17 Hatakka K, Savilahti E, Pönkä A, et al. BMJ. 2001;322(7298):1327–1332. PMID: 11387176. DOI: 10.1136/bmj.322.7298.1327 - Day-care children drinking LGG-fermented milk for 7 months; modest but consistent reductions in illness-related absences, complicated respiratory infections and antibiotic courses.

18 Uchida K, Akashi K, Kusunoki I, et al. J Nutr Food. 2005;8:39–51. - Healthy young women; fermented milk containing BB-12 increased defecation frequency in those with low stool frequency and was well tolerated even at higher intakes.

19 Matsumoto M, Kurihara S, Kibe R, et al. PLoS One. 2011;6(8):e23652. PMID: 21858192. DOI: 10.1371/journal.pone.0023652
Preclinical mechanistic study. Long-term BB-12 supplementation increased polyamine production and supported pathways linked in basic research to intestinal barrier integrity, low-grade inflammation, and healthy ageing. These findings inform scientific understanding of how BB-12 may work but are not validated clinical outcomes in humans and remain an active area of research.

20 European Patent EP2990045B1. Bifidobacterium animalis subsp. lactis for use in decreasing abdominal pain in a postmenopausal woman. Priority 26 Aug 2014. - Pooled data from two large clinical trials; BB-12 significantly reduced abdominal pain scores in postmenopausal women with low defecation frequency and weekly abdominal complaints compared with placebo.

21 Han X, Lee A, Huang S, Gao J, Spence JR, Owyang C. Gut Microbes. 2019;10(1):59–76. PMID: 30040527. DOI: 10.1080/19490976.2018.1479625. - Human intestinal enteroids and colonoids; LGG prevented IFN-gamma– and IBS fecal supernatant–induced tight-junction disruption (ZO-1, occludin) and increased permeability, supporting gut-barrier function.

Gut-brain axis (active research field)

22 Reviews of the microbiome–gut–brain axis. Front Immunol. 2025;16:1529958. DOI: 10.3389/fimmu.2025.1529958. - Describes bidirectional signalling between gut microbiota, the immune system and the brain as an active area of research.

Prevalence of gut-brain interaction disorders

23 Sperber AD, Bangdiwala SI, Drossman DA, et al. Gastroenterology. 2021;160(1):99–114. PMID: 32294476. DOI: 10.1053/j.gastro.2020.04.014. - Rome Foundation Global Study, 73,076 adults across 33 countries; more than 40% met criteria for at least one disorder of gut-brain interaction (DGBI). Belgian data reported via UZ Leuven: 38% of adults.